$63.84
0.100.16%
al cierre: Nov 13, 4:00 PM EST
$63.84
N/A
After hour: 4:00 PM EST
The Scotts Miracle Gro rose 9.3% from $58.40 to $63.84, behind the S&P 500's +12.3%. Its worst day was Mar 26 (−8.1%), and its low came Sep 28 at $48.44.
Nov 13, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.77 beat the $-1.01 estimate on $354.4M revenue (est. $354.8M); FY EPS guidance of $4.15–$4.35 against the $4.28 consensus.
−0.7% · S&P 500 0.0%
Story events cover the past 12 months · Times ET
The Scotts Miracle Gro shares fell 8.1%, while the S&P 500 fell 1.8%.
−8.1%, the year's worst day · S&P 500 −1.8%
EPS of $4.53 beat the $4.01 estimate on $1.5B revenue (est. $1.4B); FY EPS guidance of $4.15–$4.35 against the $4.29 consensus.
−4.5% · S&P 500 0.0%
The Scotts Miracle Gro shares rose 8.0%, while the S&P 500 fell 0.0%.
+8.0% · S&P 500 0.0%
The Scotts Miracle Gro closed at its highest level of the year, 25.8% above where the year started.
+8.1% · S&P 500 −0.5%
EPS of $2.82 beat the $2.49 estimate on $1.2B revenue (est. $1.2B); FY EPS guidance of $4.30–$4.45 against the $4.33 consensus.
−3.8% · S&P 500 −1.5%
The Scotts Miracle Gro closed at its lowest level of the year, 17.1% below where the year started.
−4.8% · S&P 500 −0.7%
The Scotts Miracle Gro shares rose 9.1%, while the S&P 500 rose 0.3%.
+9.1%, the year's best day · S&P 500 +0.3%
EPS of $-2.16 beat the $-2.21 estimate on $302.9M revenue (est. $306.5M); FY revenue guidance of $3.4B–$3.4B against the $3.4B consensus.
+8.7%, on 3M shares, the year's heaviest volume · S&P 500 +1.7%
Where it ended: a close of $63.84 on Nov 13, 2026. Up next: Q1 2027 earnings on Jan 27, 2027 (EPS est. $-0.97, revenue est. $355.6M).
As of the Nov 13, 2026 close
Replay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for SMG and SPY from Benzinga historical bars. Not investment advice.